N/A N=10 Pilot Study of the Comparison of the Upper Airway Dynamics of Oronasal vs Nasal Masks With PAP Treatment
Obstructive Sleep Apnea (OSA)
Primary: AHI — 42.3; 1.58 events per hour
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=550 Topical Delivery of Vitamin D3 as Vitamin D Supplementation
Vitamin D Deficiency
Primary: Level of Serum 25 OHD Level Pre-treatment and Post Treatment — 12.03; 10.36; 37.17; 10.51 ng/mL — p=0.9
Phase 3 N=380 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Stage III Kidney Wilms Tumor · Stage IV Kidney Wilms Tumor
Primary: Event Free Survival Probability — 0.79 Probability
Phase 3 N=18 Statin Therapy in the Treatment of Sepsis
Septic Shock
Primary: Time to Shock Reversal — 44.4; 28.6 hours
N/A N=19 Ultraviolet Light And Vitamin D In Subjects With Fat Malabsorption Or After Gastric Bypass Surgery
Vitamin D Deficiency · Gastrointestinal Diseases
Primary: # of Pts w/ Enhanced Vitamin D Status — 3; 3 Participants
Phase 4 N=60 A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults
Gastrointestinal Diseases
Primary: Mean Maximal Measured Plasma Concentration (Cmax) After a Single Dose — 543.78; 530.34 Nanogram per mL (ng/mL)
N/A N=17 Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Kidney Neoplasms · Carcinoma, Renal Cell · Kidney (Renal Cell) Cancer
Primary: F-18 FDG Tumor Uptake (SUV Max) — 9.8; -18.9; 34.0 SUVmax
Phase 4 N=56 Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users
Menstruation Disturbances
Primary: Bleeding Days — 65.6; 46.9 days
N/A N=20 A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma
Melanosis
Primary: Visual Analog Scale (VAS) of Improvement Rated by a Blinded Dermatologist From at Week 10 — 4.37; 4.62 units on a scale
N/A N=62 Adding Metformin to Insulin in Controlling Pregestational and Gestational Diabetes Mellitus
Gestational Diabetes Mellitus in Pregnancy
Primary: Number of Participants With Glycemic Control Over Period From 20 Weeks to 36 Weeks Gestation — 24; 27 Participants
N/A N=67 A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia
Lymphocytic Leukemia, Chronic
Primary: Percentage of Participants With Adverse Events (AEs) — 89.6 percentage of participants
Phase 2 N=50 Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Primary: Percentage of Participants Who Experienced Adverse Events During Treatment. — 96; 96 percentage of patients
N/A N=56 Accuracy of the Drager Dual-sensor Temperature Measurement System
Hypothermia; Anesthesia
Primary: The Bias Between Temperature Measured by Drager Double-sensor vs Core Temperature — -0.01; -0.13 Celsius degree
N/A N=30 Computer Assisted Instrument Guidance (CAIG) For Arterial Line Placement
Arterial and Midline Catheterization
Primary: Time Needed to Correctly Insert the Arterial or Midline Catheter. — 30.07; 44.76 Seconds
Phase 2 N=34 Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease
Anemia of Chronic Kidney Disease
Primary: Change in Serum Hepcidin With Vitamin D Intervention for Children With Chronic Kidney Disease — 48.2; 75.4 ng/ml